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Abstract
Objectives: Details of the biological variability of high-
sensitivity C-reactive protein (hs-CRP), N-terminal pro-
hormone of brain natriuretic peptide (NT-proBNP) and 
ST2 are currently lacking in patients with acute coronary 
syndrome (ACS) but are crucial knowledge when aiming 
to use these biomarkers for personalized risk prediction. 
In the current study, we report post-ACS kinetics and the 
variability of the hs-CRP, NT-proBNP and ST2.
Methods: BIOMArCS is a prospective, observational study 
with high frequency blood sampling during 1 year post-
ACS. Using 1507 blood samples from 191 patients that 
remained free from adverse cardiac events, we investi-
gated post-ACS kinetics of hs-CRP, NT-proBNP and ST2. 
Biological variability was studied using the samples col-
lected between 6 and 12 months after the index ACS, when 
patients were considered to have stable coronary artery 
disease.
Results: On average, hs-CRP rose peaked at day 2 and 
rose well above the reference value. ST2 peaked imme-
diately after the ACS but never rose above the reference 
value. NT-proBNP level rose on average during the first 
2  days post-ACS and slowly declined afterwards. The 
within-subject variation and relative change value (RCV) 
of ST2  were relatively small (13.8%, RCV 39.7%), while 
hs-CRP (41.9%, lognormal RCV 206.1/-67.3%) and NT-
proBNP (39.0%, lognormal RCV 185.2/-64.9%) showed a 
considerable variation.
Conclusions: Variability of hs-CRP and NT-proBNP within 
asymptomatic and clinically stable post-ACS patients is 
considerable. In contrast, within-patient variability of ST2 
is low. Given the low within-subject variation, ST2 might 
be the most useful biomarker for personalizing risk pre-
diction in stable post-ACS patients.
Keywords: acute coronary syndrome (ACS); C-reactive 
protein (CRP); myocardial infarction; N-terminal pro-
hormone of brain natriuretic peptide (NTproBNP); ST2; 
variability.
Introduction
Elevated serum levels of high-sensitivity C-reactive protein 
(hs-CRP), N-terminal prohormone of brain natriuretic 
peptide (NT-proBNP) and soluble ST2 (ST2) have been 
associated with adverse cardiovascular events in patients 
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with coronary artery disease (CAD) and acute coronary syn-
drome (ACS), and have been proposed in prognostic models 
[1–8]. However, the differences in serum levels between 
the patients with and without cardiovascular events are 
often not large. For example, in a study by Zebrack et al. 
among 2554 patients undergoing coronary angiography, 
in the group without CAD and the lowest event rate during 
a mean follow-up of 2 years median CRP levels was from 
1.15 mg/dL, compared median levels of 1.28 mg/dL in the 
group with the most severe CAD and highest event rate 
during follow-up [4].
While aiming for personalized risk prediction, appropri-
ate stratification of patients is crucial. Thus, it is important 
to know if differences in biomarkers levels between subjects, 
and changes over time within a patient, truly reflect differ-
ences in health state, or if it is caused by analytical or by 
biological variability. Studies on the variability of hs-CRP, NT-
proBNP and ST2 during stable health have mostly been per-
formed in (small sets of) healthy subjects, or in heart failure 
(HF) patients [9–18]. Remarkably, data on their performance 
in stable post-ACS/CAD patients is scarce [19].
Against this background, we aimed to provide a 
detailed description of the influence of an ACS on hs-CRP, 
NT-proBNP and ST2 levels, and to investigate the within- 
and between-patient variability of these biomarkers in 
serial blood samples during stable health after ACS. Our 
analyses are embedded in the BIOMarker study to iden-
tify the Acute risk of a Coronary Syndrome (BIOMArCS), 
which was specifically designed to study longitudinal bio-
marker patterns in (post-)ACS patients [20].
Materials and methods
BIOMArCS is a multi-center, prospective, observational study that 
was conducted in 18 participating hospitals in the Netherlands during 
2008–2015. The study was designed to obtain data on biomarker pat-
terns in ACS patients during 1-year follow-up. Details of the BIOMArCS 
design and main findings have been published previously [20–22].
Briefly, patients above 40 years presenting with ACS and at least 
one additional cardiovascular risk factor were eligible. Preferably, 
patients were enrolled during hospital admission, but inclusion at 
the first outpatient visit post-discharge (usually 4–6 weeks later) was 
allowed. Blood samples were collected at admission, at the day of 
hospital discharge and subsequently every fortnight during the first 
6 months after discharge. Additional blood samples were collected 
at 24, 48, 72 and 96 h after admission and at the day of hospital dis-
charge in a subset of 8% of patients, with the specific aim to study 
the evolution and normalization of biomarkers in the early post-ACS 
phase. Follow-up was terminated permanently after coronary artery 
bypass grafting, hospital admission for HF, or a deterioration of renal 
function leading to a glomerular filtration rate <30 mL/min/1.73 m2, 
as circulating biomarker concentrations may be significantly influ-
enced by these conditions.
All patients were treated to prevailing guidelines and at the dis-
cretion of the investigator. The study was approved by the medical 
Ethics Committees and conducted in accordance with the Declara-
tion of Helsinki. All patients signed informed consent for their par-
ticipation in the study.
Blood sampling and storage
Blood samples were handled and securely stored on-site within 4 h 
after venipuncture. After preparation, aliquots were frozen at −80 °C 
within 2  h after withdrawal. Samples were transported under con-
trolled conditions to the Department of Clinical Chemistry at the 
Erasmus MC for long-term storage. After all material was collected 
and follow-up was completed, batch-wise analysis of blood samples 
was performed in a central laboratory. Laboratory personnel were 
blinded for patient characteristics.
Biomarker measurements were performed in the serum EDTA 
plasma after a median average storage time of 4.9 (25th–75th percentile 
3.8–6.2) years. Hs-CRP was determined using the Coulter 5800 series 
(Beckman Coulter, Brea, CA, USA), lower limits of detection (LLOD) 
0.2 mg/L, and population reference value 5 mg/L. ST2 was determined 
with the Presage ST2 assay (Critical diagnostics, San Diego, CA, USA), 
LLOD 1.31 ng/mL, and reference value 49.3 ng/mL (male) or 33.5 ng/mL 
(female). NT-proBNP was measured with a custom-built ELISA method 
using an antibody against HRP-conjugated MAB mouse anti-human 
N-terminal proBNP (Hytest, 13G12 [4NT1C]), which shows very good 
agreement with other commercially available assays. The intra-assay 
CV was 4%, LLOD 6.25 pmol/L, and reference value 30 pmol/L.
Analysis of the biomarker stabilization patterns
For the analysis of the BIOMArCS study, hsTnI and HsTnT serum 
levels were measured in the samples of 187 patients [21]. Of these 
187 patients, 45 had a new ischemic event during the follow-up. For 
the current analysis, we removed the patients with a new ischemic 
event from the analysis set and enriched the set with 49 patients 
who had daily sampling during the first 4  days of the index ACS 
submission. Hence, our analysis set consisted of 191 endpoint-free 
patients. They contributed a median of 8 (25th–75th percentile 
5–10) repeated samples per patient (altogether 1507 samples) that 
were used for the analysis of stabilization patterns. We used lin-
ear mixed effect (LME) models to describe biomarker stabilization 
patterns over time. A maximum of two cubic splines were placed 
to model a possible non-linear evolvement. Mean values of hs-CRP, 
NT-proBNP and ST2 at each post-ACS day were then determined 
using the fitted LME models. The biomarker was considered stabi-
lized when the difference in mean level between two consecutive 
days was less than 1%.
Measures of biological variability
A coefficient of variability (CV) of a series of measurements is defined 
as 100% times the standard deviation (SD) of the measurements 
divided by their mean value (X̅̅):
= ∗CV 100% SD/ X
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According to the methods by Fraser and Harris [23], the total 
variability of a series of repeated measurements in individual sub-
jects can be split in three components, which represent the vari-
ability due to the imprecision of the analytical process (CVa), the 
intra-individual or within-subject variability (CVi) and the inter-indi-
vidual or between-subject variability (CVg). Besides these measures 
of variability, we also determined the index of individuality (II) and 
the reference change value (RCV). The RCV reflects the limit of (rela-
tive) change in biomarker values in individual subjects that can be 
explained by the combined within-subject and analytical variation 
while the II is calculated for investigating if population-based refer-
ence values are adequate. A more detailed description of the different 
measures of variability and the formulas used to calculate them can 
be found in the Supplementary Files.
Based on previous studies investigating cardiac remodeling and 
biomarker levels post-ACS, we presumed that ACS patients would be 
biochemically stable after 6 months [1, 24, 25]. Hence, for the analysis 
of biological variability, those patients that had ≥3 measurements in 
the 6–12 months post-ACS time window were selected. This resulted 
in a total of 446 samples and was limited to 98 patients.
We performed sensitivity analyses, investigating if the bio-
logical variation was influenced by the New York Heart Association 
(NYHA)-classification and Canadian Cardiovascular Society (CCS) 
grading. NYHA class and CCS grade were determined at all sampling 
moments. In our sensitivity analyses, we calculated the measures of 
biological variation while excluding patients who reported an ele-
vated NYHA-class (NYHA ≥1) and/or elevated CCS grading (CCS ≥1) 
at any sampling moment.
All statistical analyses were performed with R 3.3.1. p-Values 
below 0.05 (2-sided) were considered statistically significant.
Results
Patient characteristics
The mean age (standard deviation) of the patients was 
62.4 (10.6) years and 78% were men (Table 1). A substantial 
percentage of patients had hypertension (53%), hypercho-
lesterolemia (48%) and a family history of premature CAD 
(53%). ST-elevation myocardial infarction (STEMI) was the 
most common index event (49%). No relevant differences 
in baseline characteristics were identified between the 
two analysis sets.
Stabilization patterns
The average stabilization patterns of the three biomarkers 
of interest in the post-ACS period are shown in Figure 1. 
Hs-CRP increased until day 2, and reached on average a 
maximum level of 14.9 mg/L. Thereafter, hs-CRP steadily 
declined. The population reference value was reached 
at day 15, and the marker had stabilized at day 30. 
NT-proBNP also increased until day 2, where it reached 
an average maximum level of 94 pmol/L. NT-proBNP only 
slowly declined. The marker stabilized at day 15, but levels 
remained on average above the population reference value 
during follow-up. ST2  showed on average a maximum 
levels of 44.3 ng/mL at the day of the index ACS, which 
was well below the population reference value. Although 
still slowly declining, serum levels stabilized at day 5.
Biological variation
The median patient average serum levels in the 
6–12  months post-ACS period are 2.4  mg/L (interquartile 
range [IQR] 1.2–3.1) for hs-CRP, 54.4 pmol/L (IQR 29.1–97.8) 
for NT-proBNP and 30.2 ng/mL (IQR 25.2–35.0) for ST2. 
The distribution of the hs-CRP, NT-proBNP and ST2 meas-
urements in the 6–12 months post-ACS period are shown 
for each patient in Figure 2. All hs-CRP and ST2 measure-
ments were above the LLOD. NT-proBNP was below the 








Age, year (SD)   62.4 (10.6)   62.8 (9.5)
Male gender, n (%)   148 (77.5)   77 (78.6)
Cardiovascular risk factors, n (%)
 Diabetes mellitus   33 (17.3)   17 (17.3)
 Hypertension   101 (52.9)   52 (53.1)
 Hypercholesterolemia   91 (47.6)   53 (54.1)
 Family history of CAD   87 (53.0)   47 (59.5)
 Current smoker   80 (41.9)   41 (41.8)
History of cardiovascular disease, n (%)
 MI   50 (26.2)   30 (30.6)
 CABG   14 (7.3)   6 (6.1)
 PCI   44 (23.2)   28 (28.9)
 Stroke   19 (9.9)   7 (7.1)
Admission diagnosis, n (%)
 STEMI   94 (49.2)   48 (49.0)
 NSTEMI   72 (37.7)   36 (36.7)
 UAP   25 (13.1)   14 (14.3)
Physical examination
 Body mass index (SD)   27.5 (3.6)   27.5 (3.6)
 Killip class 1, n (%)   177 (89.4)   94 (95.9)
 Heart rate (IQR)   73 (62–84)   70 (61–81)
 Systolic blood pressure (IQR)  137 (117–152)   136 (119–151)
CABG, coronary artery bypass grafting; CAD, coronary artery 
disease; IQR, interquartile range; MI, myocardial infarction; n, 
number; PCI, percutaneous coronary intervention; SD, standard 
deviation; STEMI, ST-elevation myocardial infarction; UAP, unstable 
angina pectoris.
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the population reference in 15.5% of the samples, NT-
proBNP in 24.1%, and for ST2 in 3.5%.
Hs-CRP (CVi 41.9%, lognormal RCV 206/-67%) and NT-
proBNP (CVi 39.0%, lognormal RCV 185/-65%) displayed a 
considerable within-individual variation and correspond-
ingly wide RCVs, while the plasma concentrations of 
ST2 within a patient were rather stable (CVi of 13.8%, RCV 
40%). The within-subject variability of hs-CRP (Kruskal-
Wallis, p = 0.36) and ST2 (p = 0.17) was not influenced by 
the patients average serum levels. In contrast, the within-
subject variation of NT-proBNP (Kruskal-Wallis, p = 0.003) 
was much larger in patients with low serum concentra-
tions (Figure 3). All three studies biomarkers had an II 
below 0.6, indicating that a patient-based reference value, 
based on previous samples of the individual patient is pre-
ferred. A detailed overview of the parameters of variation 
is shown in Table 2.
Sensitivity analyses
An NYHA class ≥1 was reported at 29 sampling moments 
(6%) in 15 different patients, while a CCS ≥1 was reported 
at 49 (11%) sampling moments in 27 different patients. In 
the majority of the cases, this concerned NYHA class and 
CCS class one (44.8% and 75.5%, respectively). The CVs 
Figure 1: Temporal patterns of hs-CRP, NT-proBNP and ST2 after ACS.
Left pictures depict the washout pattern after the ACS, the right pictures show all measurements during the year of follow-up. hs-CRP, high-
sensitivity C-reactive protein; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; ST2, soluble suppression of tumorigenicity-2.
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calculated in the dataset excluding these patients, showed 
similar results as the full cohort (Supplementary Table 1).
Discussion
Levels of hs-CRP, NT-proBNP and ST2 appeared differ-
ently affected by an ACS. Both Hs-CRP and NT-proBNP 
reached maximum values at day 2, however, hereafter 
hs-CRP declined to levels below the population reference 
within 2 weeks, while the NT-proBNP only slowly declined 
and remained above the population reference value 
throughout the follow-up. ST2 was elevated at the time of 
the index ACS, but values remain below the population 
reference. Hs-CRP and NT-proBNP showed substantial 
within-subject variability and thus wide RCV, while the 
within-subject variability of ST2  measurement was low. 
The between-subject variability was much larger than the 
within-subject variability for all three biomarkers.
Hs-CRP is one of the most used biochemical marker 
of inflammation in medicine and is known to rise 
Figure 2: Distribution of measurements per patient.
Horizontal: patients ranked according to their average biomarker 
value. Vertical: Spread of biomarker measurement per patient. 
hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal 
prohormone of brain natriuretic peptide; ST2, soluble suppression 
of tumorigenicity-2.
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Figure 3: Intra-individual variability in quartiles based on average 
biomarker level.
Boxplots of individual CVis in the different biomarker quartiles. 
hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal 
prohormone of brain natriuretic peptide; ST2, soluble suppression 
of tumorigenicity-2. Median [range] of quartiles: Hs-CRP 1st: 0.8 
[0.4, 1.2] 2nd: 1.8 [1.3, 2.4], 3rd: 3.0 [2.6, 3.5], 4th: 5.1 [3.6, 21.3]. 
NT-proBNP 1st: 20 [3, 29] 2nd: 39 [29, 54], 3rd: 66 [55, 91], 4th: 174 
[100, 783]. ST2: 1st: 22.2 [13.8, 25.2] 2nd: 27.3 [25.3, 30.2], 3rd: 31.4 
[30.2, 34.9], 4th: 41.2 [35.0, 54.0].
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after ACS due to inflammation of the ischemic areas 
of the heart. In agreement with our findings, Orn et al. 
described a delayed rise of CRP and a relatively fast near- 
normalization hereafter in 42 STEMI patients [26]. Simi-
larly, among 962 patients with an episode of unstable 
CAD (NSTEMI and UAP), a peak in CRP serum concentra-
tion at 48 h after the start of symptoms was described. 
In this same population the CRP levels at 6 months was 
on average still elevated when compared to healthy con-
trols, although not above the reference value [27]. We now 
show that although the CRP levels are quickly within the 
“normal” range, it can take much longer before the levels 
actually stabilize.
Details of the parameters of variability of hs-CRP had 
not yet been described in a post-ACS population. However, 
in healthy volunteers, the within-subject variability is 
known to be considerable while the between-subject vari-
ability is even larger [9–11]. In our post-ACS patients, we 
found comparable within-subject variability and RCVs as 
reported in healthy populations, but the variation between 
post-ACS patients appeared much larger. Given the high 
within-patient variability, it would take numerous numbers 
of samples to determine the habitual value needed to use 
CRP in personalized risk prediction in clinically stable 
CAD patients. This makes sense, as hs-CRP is not a spe-
cific cardiac marker and can be influenced by many other 
factors.
NT-proBNP showed an initial rise and maximum 
value at day 2 followed by a slow decline thereafter, 
with the levels remaining above the population refer-
ence value. The early rise can be explained by the initial 
myocardial ischemia [28], while the slow decline is most 
likely caused by progressive remodeling combined with a 
degree of myocardial dysfunction post-ACS [29]. However, 
as repeated cardiac imaging was not part of our study 
protocol, we cannot confirm this. The post-ACS kinetics 
of NT-proBNP have previously been described by Taiwar 
et  al. and Lidahl et  al. in, respectively, 60 patients and 
1216 myocardial infarction patients. Similar to our study, 
they described a peak of the biomarker serum levels in the 
first 48 h after the index event and a slow decline here-
after [30, 31]. Other investigations – using a few samples 
taken weeks/months apart from each other and not spe-
cifically focusing on post-ACS kinetics –, also showed that 
the biomarker had a peak early after ACS, and only slowly 
declined between blood samples hereafter [1, 2]. Our study 
distinguishes itself from previous studies by three key ele-
ments: our study is conducted in the contemporary PCI-
era; we systematically obtained a median of 4 (IQR 4–5) 
samples per patient at regular time points during 1-year 
follow-up; we applied state-of-the-art statistical methods, 
including LME models, in order to account for intra-
patient correlation of consecutive measurements.
The biological variability of NT-proBNP in patients 
with CAD has been described earlier by Nordenksjold 
et al. in a total of 24 patients [19]. Using two samples taken 
a median of 23 (IQR 4–58) days apart, they found a CVi 
of 20.4 with a log-normal RCV of +76/−43%. We obtained 
a larger sample of patients and applied a higher blood 
sampling frequency. Also, we enrolled a homogeneous 
series of patients who were admitted for ACS, whereas 
Nordenksjold et  al. studied patients undergoing coro-
nary angiography, of whom only 50% patients ultimately 
underwent revascularization. These differences in study 
design could easily explain the differences in variability, 
and the corresponding RCVs found. The variability of NT-
proBNP has also been investigated in healthy subjects and 
HF patients. Similar to our study results, in all studies 
previously performed, NT-proBNP serum levels consist-
ently show considerable within-patient variability and 
large corresponding RCVs [12–15]. Because of this vari-
ability, a single NT-proBNP measurement does not suffice 
for determining the habitual value, and thus, also not for 
an adequate personalized risk prediction. Notably, the 
between-subject variability that we found was compara-
ble to the HF patients (CVg of 116.3%) and larger than the 
healthy subjects (54.0%) that were described by Meijers 
et  al. [15]. This can probably be explained by the larger 
Table 2: Overview of parameters of biological variation in serial measurements 6 months after ACS.
Average patient level CVa CVi CVg II RCV, % Log-normal
RCV up, % RCV low, %
CRP 2.4 (1.2–3.1) 3 42.0 99.1 0.42 116.3 206.1 −67.3
NT-proBNP 54.4 (29.1–97.8) 4 39.0 127.6 0.31 108.1 185.2 −64.9
ST2 30.2 (25.2–35.0) 5 13.4 25.4 0.56 39.7 48.4 −32.6
ACS, acute coronary syndrome; CVa, analytical coefficient of variation; CVg, interindividual coefficient of variation; CVi, intra-individual 
coefficient of variation; hs-CRP, high-sensitivity c-reactive protein; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; ST2, 
soluble suppression of tumorigenicity-2; II, index of individuality; RCV, reference change value.
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heterogeneity in health status among patient populations 
when compared to healthy populations.
The early post-ACS evolvement of serum ST2 has been 
described based on 403  NSTE-ACS patients who partici-
pated in GUSTO-IV, using blood samples at 24, 48 and 72 h 
after inclusion [5]. Similar as in our study, ST2 reached its 
maximum during the first sample and quickly declined 
hereafter. Our results add to this that, once stabilized, 
ST2 is a very stable marker with little variation over time 
in post-ACS patients. This is in line with previous studies 
investigating the biological variability of ST2, that all 
showed little within-patient variation and thus relatively 
small RCVs. Both Wu et al. and Dieplinger et al. report a 
CVi of approximately 10% in small sets of healthy subjects 
[17, 18], which was similar to the CVi in series of chronic HF 
patients [15, 16]. Interestingly, in the study by Meijers et al. 
the between-subject variability of ST2 in HF patients did 
not differ much from healthy controls (36.9% vs. 30.4%) 
[15]. Given the promising results of ST2 as a prognostic 
marker in patients with ACS and/or CAD [5–8], and the 
low within-patient variability of serum ST2 levels in post-
ACS, a single, or a few, measurements would most likely 
improve personalized risk prediction.
Limitations
The BIOMArCS study provides us with a unique platform 
to investigate the effect of ACS on the different blood bio-
marker and to investigate their parameters of variability in 
clinically stable post-ACS patients. However, a few limita-
tions of our work need discussion. Blood sampling in BIO-
MArCS was protocolized, but the exact sample moment on 
the day was not. Consequently, differences in physical activ-
ities and diet, as well as potential circadian variation could 
have influenced the measures of biological variation [32–34]. 
Still, importantly, all samples were taken between 8 am and 
4 pm, whereas the vast majority of patients had their blood 
sampling at the same time, which, apparently best fitted in 
their private schedule. Secondly, as we used one central lab-
oratory for the analysis of the blood samples, we could not 
investigate variability between different laboratories.
Conclusions
In conclusion, the within-patient variability of hs-CRP 
and NT-proBNP within asymptomatic and clinically stable 
post-ACS patients is substantial. This leads to clinically 
significant differences between serial measurements in the 
same patients. If used for personalized risk prediction, this 
would compromise the calibration and multiple samples 
would be needed in order to correctly classify the patients 
in the right risk category. In contrast, within-patient 
 variability of ST2 is low. Given the low within- subject vari-
ation, ST2 might be the most useful biomarker for person-
alized risk prediction in stable post-ACS patients.
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